Swiss biotech raises $16M to test 'undelivery mechanism' for rare liver disease
The process is grinding and often terminal, like a fine car with a transmission patched up a dozen times but still jamming and in dire need of replacement. Patients with late-stage chronic liver disease will decompensate (lose organ function) and though that instance can be treated, each time is like another jolt on the gears. Eventually, the car won’t drive. There are transplants, but over half of the patients die waiting for those.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
